Compare SHAK & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHAK | PVLA |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2014 | N/A |
| Metric | SHAK | PVLA |
|---|---|---|
| Price | $71.13 | $157.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 26 | 15 |
| Target Price | $117.29 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 2.2M | 187.1K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 354.17 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $1,445,306,000.00 | N/A |
| Revenue This Year | $16.58 | N/A |
| Revenue Next Year | $15.07 | $104,350.18 |
| P/E Ratio | $190.05 | ★ N/A |
| Revenue Growth | ★ 15.38 | N/A |
| 52 Week Low | $51.60 | $40.22 |
| 52 Week High | $110.67 | $161.38 |
| Indicator | SHAK | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 66.47 | 58.21 |
| Support Level | $52.90 | $103.38 |
| Resistance Level | $97.35 | $156.88 |
| Average True Range (ATR) | 2.90 | 11.69 |
| MACD | 1.48 | 0.41 |
| Stochastic Oscillator | 79.32 | 86.10 |
Shake Shack Inc is a roadside burger stand. It serves a classic American menu of premium burgers, hot dogs, crispy chicken, frozen custard, crinkle-cut fries, shakes, beer, wine, and more. The company's burgers are made with a whole-muscle blend of all-natural, hormone and antibiotic-free Angus beef, ground fresh daily, cooked to order, and served on a non-genetically modified organism (GMO) potato bun. Its menu focuses on food and beverages, crafted from a range of classic American foods. The company serves draft Root Beer, seasonal freshly-squeezed lemonade, organic fresh-brewed iced tea, cold brew coffee, organic apple juice, and Shack20 bottled water. Geographically, the company generates the majority of its revenue from the United States.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.